Targretin oral (bexarotene oral) / ReXceptor - LARVOL DELTA

Comparison of Systemic and Topical Retinoids and the Association of Inflammatory Bowel Disease in Ichthyosis Patients: A Population-Based Cohort Study (AAD 2026) - "Patients with acquired ichthyosis, congenital ichthyosis , or ichthyosis vulgaris treated with systemic retinoids such as alitretinoin, isotretinoin, etretinate, and acitretin (n=449) were identified using validated ICD-10 codes. A comparator cohort treated with topical retinoids such as adapalene, tazarotene, bexarotene, alitretinoin, and tretinoin (n=449) was established... These findings indicate that the protective association is specific to systemic retinoid therapy and highlights the importance of treatment selection in patients with ichthyosis who have comorbid or potential IBD. Future studies should further explore the role of systemic retinoids as potential disease-modifying agents for IBD and other inflammatory conditions in ichthyosis patients."

Clinical • Atopic Dermatitis • Crohn's disease • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • Vitiligo

A Comparison of the Protective effects of Systemic vs Oral Retinoids on Non Melanoma Skin Cancers in Acne Patients: A Retrospective Cohort Study (AAD 2026) - "Two matched cohorts were created: systemic retinoids (alitretinoin, isotretinoin, etretinate, acitretin; n=34,851) and topical retinoids (adapalene, tazarotene, bexarotene, tretinoin; n=34,851). Patients with known NMSC risk factors (chemical exposures, HPV, or use of BRAF inhibitors, cyclosporine, voriconazole, hydrochlorothiazide) were excluded... The enhanced protective effect of systemic retinoids may reflect their deeper influence on keratinocyte turnover and skin cell regeneration compared to topical formulations. Further studies are warranted to clarify the relative efficacy of individual agents and optimize retinoid prophylaxis in high-risk patients."

Retrospective data • Acne Vulgaris • Basal Cell Carcinoma • Genetic Disorders • Kaposi Sarcoma • Non-melanoma Skin Cancer • Sarcoma • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma

Activation of the RXR nuclear receptor improves survival and the therapeutic window of immunotherapy in murine breast cancer (AACR 2026) - "Bexarotene, the only approved RXR agonist, is used in refractory cutaneous T cell lymphoma but lacks effect on solid tumors. In conclusion, MSU42011 increased recruitment and activation of CD8 T cells and a decrease of tumor promoting myeloid cells in both HER2+ and TNBC murine mammary tumors. These data, in combination with our previous work shows that the RXR agonist MSU42011 reduces tumor growth by modulating the tumor microenvironment and can safely be combined with anti-PD1."

IO biomarker • Preclinical • Breast Cancer • Cutaneous T-cell Lymphoma • Gastric Cancer • Hematological Malignancies • HER2 Breast Cancer • HER2 Positive Breast Cancer • Lung Cancer • Lymphoma • Oncology • Solid Tumor • T Cell Non-Hodgkin Lymphoma • Triple Negative Breast Cancer • CD69 • CD8 • HER-2 • ITGAM • ITGAX • MRC1 • PD-L1

Nationwide epidemiologic and economic burden analysis of neurologic disorders associated with cancer treatment (AACR 2026) - "Higher mean incremental daily dose was significantly associated with increased CIND hazard, with oral agents showing HRs per 1-SD from 1.09-2.23 (bexarotene, capecitabine, hydroxyurea, mercaptopurine, tretinoin; all p≤0.046) and IV methotrexate showing HR 1.34 (95% CI 1.00-1.79; p=0.048). In this nationwide cohort, CIND is common, often delayed, and shaped by route of administration, indication, dose intensity, and patient comorbidity. CIND care concentrates substantial utilization and financial burden in chemotherapy exposed populations, underscoring the need for dose optimized regimens, proactive surveillance, and better supportive care strategies."

Clinical • HEOR • Oncology

Exploring the impact of RAS mutations in abdominopelvic Rosai Dorfman disease on responsiveness to targeted therapies: A case control study (AACR 2026) - "All 4 patients received frontline cobimetinib with 3 achieving at least a partial response and two demonstrating near-complete resolution of all known disease sites...One patient eventually progressed during dose reduction and was transitioned to trametinib; another passed from non-RDD cardiac causes.We also reviewed an age-matched cohort (63-79) of 4 patients with abdominopelvic RDD lacking baseline RAS/MAPK pathway or other driver mutations...Management strategies varied as only two patients received frontline systemic therapy, one sequentially with bexarotene followed by rituximab and the other with vinblastine... Patients with RAS-mutated abdominopelvic RDD tend to experience a more aggressive disease course compared to wildtype but demonstrate marked sensitivity to MAP Kinase pathway-targeting therapies. The findings of this study are limited by small sample size; ongoing efforts are underway to expand with a multi-center cohort."

Clinical • Oncology • CD163 • CD68 • DNMT3A • KRAS • NRAS • RAS • RTEL1

Recent Advances in Dermatopathology: Staying Ahead of Your Next Challenging Case (USCAP 2026) - "Dupilumab was discontinued and she was started on bexarotene and ropeginterferon-alfa-2b with complete remission. The reaction usually resolved with discontinuation of therapy.10 In conclusion, patients with adult-onset atopic dermatitis and an atypical presentation of their disease would benefit from a skin biopsy before initiating dupilumab and needs to be followed closely after therapy at 3-4 months to assess for progression or lack of response. Evening Specialty Presentation (PDF): Click to View"

Clinical • Atopic Dermatitis • Cutaneous T-cell Lymphoma • Dermatopathology • Hematological Malignancies • Immunology • Lymphoma • Mycosis Fungoides • Pruritus • T Cell Non-Hodgkin Lymphoma • CD4 • CD5 • CD7 • CD8 • IL13 • IL4R • TNFRSF8

Positive net antiviral benefit of bexarotene against patient-derived archetype and rearranged BK polyomavirus isolates. (PubMed, Antiviral Res) - "They had a stronger antiviral activity than acitretin, which was more strain-specific and tazarotenic acid showing only modest effects...The CDK inhibitors Ro-3306 and roscovitine exhibited limited or no positive NAB, respectively. Notably, although the mTOR inhibitor sirolimus appeared to have additive antiviral effects when applied together with bexarotene, it displayed a negative NAB, rather attributing its activity to changes on cell growth/viability. In summary, bexarotene represents a promising therapeutic repurposing candidate for BKPyV reactivation in transplant patients, suggesting clinically achievable therapeutic efficacy. Clinical validation is warranted to translate these findings into therapeutic solutions for transplant recipients."

Journal • Nephrology • Renal Disease • Transplantation

From Crops to Transformation: Type B Lymphomatoid Papulosis Evolving into CD30+ Mycosis Fungoides with Large-Cell Transformation (AAD 2026) - "Patient History: A 74-year-old man with hypertension, hyperlipidemia, and palmoplantar psoriasis on apremilast since 2022 presented in September 2024 for routine skin examination...Biopsy revealed lymphomatoid papulosis (LyP) type B. At six-week follow-up, lesions became more erythematous with crusting, prompting initiation of methotrexate 15 mg weekly with folic acid, with partial improvement. Targretin was attempted but not tolerated...He was referred to oncology for initiation of brentuximab vedotin...Diagnosis: CD30+ mycosis fungoides with large cell transformation arising in a patient with prior LyP type B. This case highlights the diagnostic overlap between LyP and MF and illustrates disease evolution toward large cell transformation. Longitudinal correlation, repeat biopsies, and recognition of CD30+ transformation are essential for accurate diagnosis and management of cutaneous T-cell lymphoproliferative disorders."

Cardiovascular • Cutaneous T-cell Lymphoma • Dermatology • Dyslipidemia • Hematological Malignancies • Hypertension • Immunology • Lymphoma • Mycosis Fungoides • Oncology • Psoriasis • TNFRSF8

Acute and delayed mogamulizumab-associated rash with multiple pathologic subtypes in a patient with folliculotropic mycosis fungoides (AAD 2026) - "A 68-year-old man with relapsed and refractory FMF started mogamulizumab after failing NBUVB, methotrexate, interferon, prednisone, brentuximab, and bexarotene treatment. However, our patient has consistent B0 blood involvement. Future studies should assess MAR-associated long-term prognosis in FMF."

Clinical • Cutaneous T-cell Lymphoma • Dermatology • Dermatopathology • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Oncology • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma

Brain Single-Cell Transcriptional Responses to Bexarotene-Activated RXR in an Alzheimer's Disease Model. (PubMed, Int J Mol Sci) - "These findings clarify the molecular complexity of RXR-mediated regulation, revealing the cellular origins of bexarotene's known effects as well as novel, cell-type-specific responses. This study provides mechanistic insights into RXR-targeted interventions and supports APOE-associated pathways as promising therapeutic targets in AD."

Journal • Alzheimer's Disease • CNS Disorders • Inflammation • Metabolic Disorders • Solid Tumor • APOE

Dose-stratified analysis of acitretin vs. bexarotene in mycosis fungoides: a retrospective cohort study. (PubMed, Br J Dermatol) - No abstract available

Journal • Retrospective data • Cutaneous T-cell Lymphoma • Dermatology • Mycosis Fungoides • Oncology

Orthogonal Temperature-Related Intensity Change and Time-Resolved Förster Resonance Energy Transfer High-Throughput Screening Platform for the Discovery of SLIT2 Binders. (PubMed, Bio Protoc) - "• Reproducible analysis: standardized thresholds for TRIC hits and relative IC50 reporting for partial inhibitors. • Generalizable to other extracellular glycoproteins and ligandable protein-protein interactions (PPIs)."

Journal • Immune Modulation • Immunology • Oncology • SLIT2

From last chance to chronic condition: Success for a young lymphoma patient through total skin electron irradiation (DKK 2026) - "Palliative therapy with bexarotene and ECP was initiated, although there was little hope for long-term therapeutic success...The patient transitioned to maintenance therapy with brentuximab... TSEI led to a good response in the skin, lymph nodes, and blood. Thanks to TSEI, we were able to transition to maintenance therapy and discharge the patient to home care. The authors declare no conflict of interest."

Clinical • Cardiovascular • Cutaneous T-cell Lymphoma • Graft versus Host Disease • Hematological Disorders • Hematological Malignancies • Hypotension • Immunology • Lymphoma • Mycosis Fungoides • Palliative care • Pruritus • TNFRSF8

Pd-catalyzed synthesis of deuterated olefins from (hetero)arenes and ketones via a cross-coupling approach. (PubMed, Chem Commun (Camb)) - "Here, we have developed a novel, straightforward approach for the synthesis of deuterium olefins from arenes, heteroarenes, and ketones, with broad substrate scope, high yields, and excellent deuterium incorporation. The practical applications of this methodology, as demonstrated through the synthesis of deuterium-containing active pharmaceutical drugs such as bexarotene, isocombretastatin-4 (IsoCA-4), and CC-5079, aim to show its relevance and potential impact in the pharmaceutical industry."

Journal

Management of Mycosis Fungoides With Chlormethine Hydrochloride Gel in Combination With Systemic Therapies: A Case Series. (PubMed, Case Rep Dermatol Med) - "All patients were treated with chlormethine hydrochloride gel in combination with other skin-directed and systemic therapies, including bexarotene, methotrexate, topical steroids, extracorporeal photopheresis, donor lymphocyte infusion and interferon-α (IFN-α) 2a...The combination regimens were generally well tolerated, with associated adverse events being inflammation, pruritus and erythema. This case series reports on the efficacy and safety of chlormethine hydrochloride gel in combination with other topical and systemic therapies in reducing the skin lesion severity in patients with Stage I-IV MF in different real-world settings."

Journal • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Oncology • Pruritus • T Cell Non-Hodgkin Lymphoma • IFNA1

RXR Agonist V-125 Induces Distinct Transcriptional and Immunomodulatory Programs in Mammary Tumors of MMTV-Neu Mice Compared to Bexarotene. (PubMed, Biomedicines) - " V-125 but not bexarotene reprograms tumor transcriptional programs and the immune landscape in an anti-tumor manner in the MMTV-neu mouse model and in in vitro models of HER2+ breast cancer. This highlights its promise as a selective RXR agonist with anti-tumor and immunomodulatory activity in HER2+ breast cancer."

Journal • Preclinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Immune Modulation • Immunology • Metabolic Disorders • Oncology • Solid Tumor • CD8 • CHI3L1 • HER-2 • MRC1 • NRG1

Potential effects of bexarotene on neural development and function in zebrafish embryos. (PubMed, Biomed Pharmacother) - "Bexarotene activates the Wnt signaling pathway, and treatment with the Wnt inhibitor IWR-1 can partially rescue the neurodevelopmental impairments in embryos. In summary, bexarotene offers new insights into the potential neurodevelopmental risks in zebrafish embryos, emphasizing the importance of preventing drug side effects and ensuring the safe and rational use of medications to protect the health of living organisms."

Journal • CNS Disorders • Cutaneous T-cell Lymphoma • Developmental Disorders • Hematological Malignancies • Lymphoma • Oncology • Pain • Psychiatry • Solid Tumor • T Cell Non-Hodgkin Lymphoma • ATOH1 • GFAP • OLIG2

A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Memorial Sloan Kettering Cancer Center | Trial completion date: Mar 2026 ➔ Mar 2027 | Trial primary completion date: Mar 2026 ➔ Mar 2027

Trial completion date • Trial primary completion date • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Non-Hodgkin’s Lymphoma • Oncology • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma

Single-Cell Transcriptomics and Integrated Bioinformatic Analysis Reveal Critical Biomarkers and Immune Infiltration Characteristics in Osteoarthritis. (PubMed, Genet Res (Camb)) - "Additionally, molecular docking studies suggested that bexarotene has a favorable binding affinity for NR4A2, BMP1, and AVPR1A, making it a promising therapeutic candidate. Our findings provide new insights into the molecular landscape of OA, offering valuable biomarkers and therapeutic targets for future OA interventions."

Biomarker • Journal • Immunology • Inflammation • Osteoarthritis • Pain • Rheumatology • NR4A2 • TGFB1

Mogamulizumab plus etoposide in the management of mycosis fungoides with blood involvement: a case report. (PubMed, Ther Adv Hematol) - "The patient achieved a partial response with methotrexate but discontinued after ~12 months due to elevated transaminases. Following treatment with bexarotene then gemcitabine, CHOP chemotherapy was initiated in December 2019, but, after a period of partial skin response, the patient relapsed with progression of skin lesions...Disease progression in the skin occurred in December 2020; mogamulizumab was continued, and the patient achieved remission with the addition of etoposide and prednisone in August 2021...In October 2022, the patient was diagnosed with large cell CD30+ transformation, and the therapeutic approach was changed to extracorporeal photopheresis, brentuximab vedotin, and topical steroids. The patient died in February 2023 due to sepsis. Our experience adds to the limited evidence that mogamulizumab may be continued in combination with etoposide following disease progression in patients with MF with blood involvement; however, more research is needed on the..."

Journal • Cutaneous T-cell Lymphoma • Dermatology • Dermatopathology • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Mycosis Fungoides • Oncology • Pain • Septic Shock • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma • TNFRSF8

Identification of prognostic genes associated with mitochondria and macrophage polarization in prostate adenocarcinoma based on transcriptome and Mendelian randomization analysis. (PubMed, Discov Oncol) - "This study identified seven prognostic genes and provided a new theoretical basis for exploring immune defense mechanisms and targeted therapeutic drugs in PRAD."

Journal • Oncology • Prostate Adenocarcinoma • Prostate Cancer • NTHL1 • SLC25A3

RXR-Mediated Remodeling of Transcriptional and Chromatin Landscapes in APP Mouse Brain: Insights from Integrated Single-Cell RNA and ATAC Profiling. (PubMed, Cells) - "We used Bexarotene-treated APP/PS1ΔE9 mice to study RXR-mediated regulatory mechanisms by integrating single-nucleus ATAC-seq (snATAC-seq) with single-cell RNA-seq (scRNA-seq) and validating differentially accessible chromatin peaks using RXR ChIP-seq...This study demonstrates that combining scRNA-seq, snATAC-seq, and ChIP-seq enables comprehensive analysis of RXR-mediated transcriptional regulation. RXR activation orchestrates cell-type-specific chromatin remodeling of gene networks controlling neuroinflammation, lipid metabolism, and synaptic signaling, providing mechanistic insights into RXR-dependent transcriptional programs in Alzheimer's disease pathology."

Journal • Preclinical • Alzheimer's Disease • CNS Disorders • Inflammation • Metabolic Disorders

Basic Science and Pathogenesis. (PubMed, Alzheimers Dement) - "Bexarotene upregulates RXR-controlled gene networks in major brain cell types, including microglia and endothelial cells. The combined analysis of single-cell transcriptomics, ATAC-seq, and ChIP-seq provides new insights into how RXR activation may restore brain homeostasis by regulating neuroinflammation, amyloid deposition, and neuronal damage. This research highlights the complexity of TF signaling pathways and their potential for therapeutic use in AD."

Journal • Alzheimer's Disease • CNS Disorders • Inflammation • Metabolic Disorders • Solid Tumor

P159 Use of Besremi® (pegylated interferon-alfa-2b) in the treatment of cutaneous T-cell lymphoma. (PubMed, Br J Dermatol) - "Four patients moved from Pegasys directly to other therapies due to disease progression or lack of control (two brentuximab, one bexarotene and one total skin electron beam)...However, we highlight that palpitations are reported as a common side-effect of Besremi in the product literature. We report ongoing results from the use of Besremi in MF/SS, discussing dosing, efficacy, safety and monitoring."

Journal • Cough • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Oncology • Respiratory Diseases • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma

The RXR agonist IRX4204 promotes cytotoxicity of Her2+ breast cancer cells by Her2-targeted CAR-T cells (SABCS 2025) - "IRX4204 is far more RXR selective than bexarotene, being devoid of RAR, LXR, PPAR gamma nuclear receptor agonism. With our collaborators we have previously reported that: (1) IRX4204 has synergistic cytotoxic effects with Her2-targeted antibodies, Her2-tyrosine kinase inhibitors, and paclitaxel on Her2+ breast cancer cell lines; (2) IRX4204 promotes apoptosis of Her2+ breast cancer cells; (3) IRX4204 promotes in vivo CD8 T-cell infiltration into murine Brca1 mutant breast cancer tumors... Combination of the RXR agonist IRX4204 with Her2-targeted CAR-T cells showed a dose dependent increase in CAR-T infiltration and death of spheroids of Her2+ SKBR3 breast cancer cells in vitro. These promising results support further development of Her2-targeted CAR-T cells, and combination of such cells with the RXR agonist IRX4204 as a therapeutic option for patients with advanced Her2+ breast cancer."

CAR T-Cell Therapy • IO biomarker • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • BRCA1 • CD8 • HER-2 • ICAM1 • PPARG